

King Pharmaceuticals, Inc. Research and Development CentreGreen Two, Suite 300 4000 CentreGreen Way Cary, NC 27513

> Eric G. Carter, PhD, MD Chief Science Officer

May 30, 2008

Dear Healthcare Professional:

We would like to inform you that after careful consideration, King Pharmaceuticals®, Inc. has decided to discontinue the manufacture of Intal® Nebulizer Solution (cromolyn sodium inhalation solution, USP). As of the date of this letter, supplies still exist at pharmacies and wholesalers, so the exact date of product unavailability is not known. This decision is based upon many factors, including our understanding of current medical therapy and the availability of alternative asthma therapies.

INTAL® Nebulizer Solution is distributed through King Pharmaceuticals®, Inc. Since no additional product will be manufactured, INTAL® Nebulizer Solution will not be available after current King, pharmacy, and wholesaler supplies are exhausted.

If you have any questions or concerns, you may contact our Professional Information Services Department at 800-776-3637.

INTAL® Nebulizer Solution is a prophylactic agent indicated in the management of patients with bronchial asthma.

Important Safety Information:

INTAL[®] Nebulizer Solution is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or other ingredients in this preparation. **INTAL[®] has no role in the treatment of status asthmaticus.** Anaphylactic reactions with cromolyn sodium administration have been reported rarely. INTAL[®] Nebulizer Solution should be used in a power-driven nebulizer with an adequate airflow rate equipped with a suitable face mask or mouthpiece. The following adverse reactions have been associated with INTAL[®] Nebulizer Solution cough, nasal congestion, nausea, sneezing and wheezing.

Sincerely,

Eric Carter, PhD, MD Chief Science Officer

Please see accompanying full Prescribing Information.

INTAL is a registered trademark of King Pharmaceuticals Research and Development, Inc., a wholly owned subsidiary of King Pharmaceuticals, Inc.

Copyright © 2008 King Pharmaceuticals», Inc. All rights reserved. MSB0002 Printed in U.S.A. 5/2008